Skip to main content

Galapagos NV ADR(GLPG-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Galapagos NV ADR

GEN DE WITTELAAN L11 A3
MECHELEN C9 2800 BEL
P: 321-534-2900
F: +32 15342901
http://www.glpg.com

Sectors & Indices

Sector
Industry
Employees

Profile

Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.

Key Executives

NameTitle
Paulus StoffelsCEO/Chairman of Supervisory Board/Director
Thad Allen HustonCFO/COO/Executive VP
Valeria CnossenExecutive VP/General Counsel
Annelies MissottenExecutive VP/Other Executive Officer

More from The Globe